CUE-101 Gets Fast Tracked for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
OncLive,
The FDA has granted a fast track designation to CUE-101 for use as a monotherapy and in combination with pembrolizumab in…
The FDA has granted a fast track designation to CUE-101 for use as a monotherapy and in combination with pembrolizumab in…
Under the terms of the agreement, Cue Biopharma will conduct a Phase 1 study, KEYNOTE-A78, evaluating CUE-101 in combination…
- Ongoing Phase 1 dose escalation and expansion study with CUE-101 as a monotherapy in post first-line recurrent/metastatic…
- Ongoing Phase 1 dose escalation and expansion study with CUE-101 as a monotherapy in post first-line recurrent/metastatic…